VTAK: Catheter Precision Net earnings per share (EPS TTM)

VTAK (Catheter Precision Inc) - company brandmark

Catheter Precision's experienced management is actively implementing systems in US hospitals, developing synergy with cardiac centers through the integration of VIVO software for arrhythmia treatment. This 12-month EPS chart demonstrates the strategy's effectiveness, where -7.40 determines the current value of the metric. However, logistics disruptions in electronics supplies and export sanctions on medical equipment are constraining revenue growth.

Catheter Precision Corporation (VTAK) - Earnings per share for the last four quarters from 02/21/2024 to 10/05/2026

Analytical breakdowns for Catheter Precision Inc (VTAK)

- stock price and consensus target price:
Stock Price Catheter Precision|VTAK - Fair Value Consensus
- market capitalization information:
Market Capitalization Catheter Precision, Inc.|VTAK - Total Enterprise Value
- business book valuation details:
Accounting Value per Share Catheter Precision|VTAK - Total Net Assets|Market Capitalization to Book Value Ratio catheterprecision.com|VTAK - Company Assets
- debt and liquidity details:
Debt to Equity Catheter Precision|VTAK - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio Catheter Precision Corp|VTAK - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Catheter Precision, Inc.|VTAK - Long-Term Liabilities|Company Short-Term Debt Catheter Precision|Quick Ratio catheterprecision.com
- earnings and valuation multiples indicators:
VTAK - Company Net Income|Projected Future Earnings Catheter Precision|VTAK - Price to Earnings Ratio|Forward P/E Multiple Catheter Precision, Inc.|VTAK - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Catheter Precision, Inc.|VTAK - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Catheter Precision|VTAK - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months catheterprecision.com|VTAK - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Catheter Precision
General company analysis:VTAK - Catheter Precision
Mass-produced product of Catheter Precision Corporation

Analyzing real business returns is critical for capital protection amid uncertainty. This indicator measures net profit distributed per share annually, neutralizing short-term volatility. By analyzing the rolling annual earnings per share, an investor assesses the impact of cost inflation on the bottom line. For Catheter Precision (VTAK), this trend reflects strained financial health. Low commercialization rates for cardiac systems make this metric sensitive to any operational expenses.

Key competitors

Regeneron Pharmaceuticals - Net earnings per share (EPS TTM)|Earnings per share for the trailing year IRTC (irhythmtech.com)|LNTH: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Mineralys (MLYS)|Net earnings per share for the last 12 months HTFL|KMTS (Kestra Medical Corp) - Earnings per share for the last four quarters|Net earnings per share (EPS TTM) ESPR|AMRN - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Anteris Technologies AVR|Earnings per share for the trailing year TNYA|CVRX: Net earnings per share for the last 12 months|Earnings per share for the trailing year MIST (Milestone Pharmaceuticals Inc)|cardiolrx.com (CRDL) - Earnings per share for the last twelve months|Earnings per one share for the last 12 months BEAT (heartbeam.com)|Earnings per share for the last twelve months Tenax Therapeutics, Inc.|ADGM: Earnings per share for the trailing year|Net earnings per share (EPS TTM) BCDA|ABIO - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) ACST (Acasti Pharma Inc.)|AVTE - Net earnings per share for the last 12 months|Verve - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters Windtree Therapeutics WINT